The changes are explored in an article in today's Washington Post:
A post-election e-mail to executives at the drug company GlaxoSmithKline details just how tough. "We now have fewer allies in the Senate," says the internal memo, obtained by The Washington Post. "Thus, there is greater risk over the next two years that bad amendments will be offered to pending legislation." The company's primary concerns are bills that would allow more imported drugs and would force price competition for drugs bought under Medicare.
It should be interesting to see how, or if, these changes affect Seventh District Congressman Roy Blunt, whose rise to power in Congress has been accompanied by a partnership with K Street lobbyists.